Best High Tech Stocks To Own For 2018


Small cap mobile gaming stock SPYR Inc (OTCMKTS: SPYR) has just signed a licensing agreement with CBS Consumer Products that will allow the incorporation of intellectual property (IP) from various Star Trek television series in future updates to and expansions of its game Pocket Starships. How much could that be worth to SPYR Inc? Consider the following net worthestimates published by Fortune last summer for the actors/actresses who were made famous by the original series (thus, guaranteed recurring income from the fan convention circuit) and just how much theyhave made mostly from having once been in the series:

William Shatner, $100 million Leonard Nimoy, $45 million DeForest Kelley (Dr. McCoy), $5 million James Doohan (Lt. Commander Montgomery Scotty Scott), $7 million Nichelle Nichols (Uhura), $8 million George Takei (Hikaru Sulu), $12 million Walter Koenig (Ensign Pavel Chekov), $8 million Majel Barrett (Nurse Chapel + computer voice), $60 million-plus (she was also wife of show creator Gene Roddenberry)


Creator Gene Roddenberry also made his estimated $500 million fortune off of his creation and its many spin-offs while Rick Berman, who was the executive producer of several later series, then made a comfortable living off the franchise.

Best High Tech Stocks To Own For 2018: State Bank Financial Corporation.(STBZ)

Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    J P Morgan Chase & Co (NYSE: JPM): Free Stock Analysis Report
     
    Comerica Incorporated (NYSE: CMA): Free Stock Analysis Report
     
    Wells Fargo & Company (NYSE: WFC): Free Stock Analysis Report
     
    Citigroup Inc. (NYSE: C): Free Stock Analysis Report
     
    Wintrust Financial Corporation (NASDAQ: WTFC): Free Stock Analysis Report
     
    Synovus Financial Corp. (NYSE: SNV): Free Stock Analysis Report
     
    State Bank Financial Corporation. (NASDAQ: STBZ): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

Best High Tech Stocks To Own For 2018: Regeneron Pharmaceuticals, Inc.(REGN)


Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…


    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Ben Levisohn]

    It hasn’t been an easy time for investors inRegeneron Pharmaceuticals (REGN) recently…and today’s price action is likely to reinforce the sense of whiplash they must be feeling.


    Agence France-Presse/Getty Images

    What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.


    Fast forward to this afternoon, and and now they’re up nearly 3%. Credit Suisse analyst Alethia Young and team explain why the injunction outweighs the earnings:

    Company issued Eylea guidance for 2017- they guided single digit
    percentage growth over 2016. Consensus had been for 12% growth and we
    had modeled 11% growth.

    EPS for 4Q came in at $3.04 in line with $3.04 consensus. Since the company has already provided OpEx guidance for 2017 and the Eylea 4Q estimate ahead of today we think earnings are less of a focus.

    We are curious where in the single digit percentage growth for Eylea the company means- 9% YoY growth wouldnt be too far from consensus vs. 3%
    growth…


    As we wrote last night, we would expect shares to trade up due to the injunction stay. We would expect shares to be up 2-4% from the injunction stay, but the effect might be muted somewhat by the Eylea guide. We would guess shares might be up 1 to 3% today.

    Shares ofRegeneron Pharmaceuticals have gained 2.8% to $363.04 at 1:57 p.m. today, while the iS

Best High Tech Stocks To Own For 2018: Seadrill Limited(SDRL)

Advisors’ Opinion:

  • [By Jason Hall]

    Shares of a number of offshore drilling stocks are up big on Friday following the announcement of Q4 earnings fromNoble Corporation Ordinary Shares (NYSE:NE). Noble’s shares are leading the way today, up over 12% as of 2:50 p.m. EST, butSeadrill Ltd(NYSE:SDRL) stock is also up more than 10%, whileENSCO PLC(NYSE:ESV) andDiamond Offshore Drilling Inc(NYSE:DO) are both up around 5%:

  • [By Lisa Levin]

    Seadrill Ltd (NYSE: SDRL) shares dropped 58 percent to $0.706. Seadrill and its banking group agreed to extend a series of key dates as part of restructuring efforts.

  • [By Chris Lange]

    Seadrill Ltd. (NYSE: SDRL) will to share its latest quarterly earnings on Tuesday. The consensus estimates call for $0.22 in EPS and $721.81 million in revenue. Shares were at $2.35 in Friday trading, in a 52-week range of $1.57 to $7.49. The consensus price target is $1.96.

  • [By Paul Ausick]

    SeaDrill Ltd. (NYSE: SDRL) dropped about 27.5% on Friday to record a new 52-week low of $1.21 against a high of $7.49. The stock closed at $1.67 on Thursday. Volume was more than double the daily average of around 14 million shares. The company had no specific news Friday.

Best High Tech Stocks To Own For 2018: Silicom Ltd(SILC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Silicom Ltd. (NASDAQ: SILC) shares were also up, gaining 17 percent to $45.45. Silicom reported a major new design win with $17 million in purchase orders.

Best High Tech Stocks To Own For 2018: Eastman Kodak Company(KODK)


Advisors’ Opinion:

  • [By Lee Jackson]

    Another famous American company caught a seller last week. Eastman Kodak Co.(NYSE: KODK) had a 10% owner selling shares. Blue Mountain Capital sold a total of 1,353,653 shares, and prices ranged from $11.54 to $11.75 a share. The total for the sale was set at $16 million. The shares closed Friday at $11.50, in a 52 week range of $10 to $17.30. There was no consensus target as the stock is not followed on Wall Street.

  • [By William Patalon III]

    One of those analysts was a gent named Michael W. Ellmann, a onetime Shakespearian literature professor who’d become a securities analyst for Wertheim Schroder & Co. in New York. Michael was covering Eastman Kodak Co. (NYSE: KODK) for Schroder when I took over the Kodak beat for Gannett Newspapers, and we became fast friends.

  • [By William Patalon III]

    The first trade spat that I covered during my newspaper days was one back in the mid-1990s that pitted Eastman Kodak Co. (NYSE: KODK) against Fujifilm Holdings Corp. (OTC ADR: FUJIY).

Best High Tech Stocks To Own For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Leave a Reply

Your email address will not be published.